Robert E. Landry's Insider Trades & SAST Disclosures
Robert E. Landry's most recent trade in Cytokinetics Inc was a trade of 10,880 Non-Qualified Stock Option (Right to Buy) done . Disclosure was reported to the exchange on May 14, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Robert E. Landry.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
Showing you 100 results sorted by most recent dates.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cytokinetics Inc | Robert E. Landry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2025 | 10,880 | 10,880 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Robert E. Landry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2025 | 7,333 | 7,333 (0%) | 0% | 0 | Common Stock | |
| Cytokinetics Inc | Robert E. Landry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 25,538 | 25,538 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Regeneron Pharmaceuticals,... | Robert Landry E. | EVP Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2024 | 400 | 11,787 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharmaceuticals,... | Landry Robert E. | EVP Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 378.98 per share. | 02 Feb 2024 | 400 | 23,974 (0%) | 0% | 379.0 | 151,592 | Common Stock |
| Regeneron Pharmaceuticals,... | Landry E. Robert | EVP Finance CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 956.65 per share. | 02 Feb 2024 | 281 | 23,693 (0%) | 0% | 956.7 | 268,819 | Common Stock |
| Regeneron Pharmaceuticals,... | E. Landry Robert | EVP Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2024 | 400 | 12,187 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharmaceuticals,... | E. Landry Robert | EVP Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 378.98 per share. | 31 Jan 2024 | 400 | 23,856 (0%) | 0% | 379.0 | 151,592 | Common Stock |
| Regeneron Pharmaceuticals,... | Landry Robert E. | EVP Finance CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 953.42 per share. | 31 Jan 2024 | 282 | 23,574 (0%) | 0% | 953.4 | 268,864 | Common Stock |
| Regeneron Pharmaceuticals,... | E. Landry Robert | EVP Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2024 | 1,100 | 13,087 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharmaceuticals,... | E. Robert Landry | EVP Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 378.98 per share. | 23 Jan 2024 | 1,100 | 24,084 (0%) | 0% | 379.0 | 416,878 | Common Stock |
| Regeneron Pharmaceuticals,... | Landry E. Robert | EVP Finance CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 948.50 per share. | 23 Jan 2024 | 776 | 23,308 (0%) | 0% | 948.5 | 736,036 | Common Stock |
| Regeneron Pharmaceuticals,... | E. Robert Landry | EVP Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 378.98 per share. | 23 Jan 2024 | 500 | 23,808 (0%) | 0% | 379.0 | 189,490 | Common Stock |
| Regeneron Pharmaceuticals,... | Landry Robert E. | EVP Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2024 | 500 | 12,587 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharmaceuticals,... | Landry E. Robert | EVP Finance CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 951.26 per share. | 23 Jan 2024 | 352 | 23,456 (0%) | 0% | 951.3 | 334,844 | Common Stock |
| Regeneron Pharmaceuticals,... | Landry Robert E. | EVP Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jan 2024 | 500 | 14,187 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharmaceuticals,... | Landry E. Robert | EVP Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 378.98 per share. | 17 Jan 2024 | 500 | 23,338 (0%) | 0% | 379.0 | 189,490 | Common Stock |
| Regeneron Pharmaceuticals,... | Landry Robert E. | EVP Finance CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 932.34 per share. | 17 Jan 2024 | 354 | 22,984 (0%) | 0% | 932.3 | 330,048 | Common Stock |
| Regeneron Pharmaceuticals,... | E. Landry Robert | EVP Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 378.98 per share. | 04 Jan 2024 | 500 | 22,948 (0%) | 0% | 379.0 | 189,490 | Common Stock |
| Regeneron Pharmaceuticals,... | E. Robert Landry | EVP Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2024 | 500 | 15,487 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharmaceuticals,... | Landry Robert E. | EVP Finance CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 917.05 per share. | 04 Jan 2024 | 342 | 22,606 (0%) | 0% | 917.0 | 313,631 | Common Stock |
| Regeneron Pharmaceuticals,... | E. Robert Landry | EVP Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2024 | 1,100 | 15,987 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharmaceuticals,... | Landry E. Robert | EVP Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 378.98 per share. | 02 Jan 2024 | 1,100 | 23,136 (0%) | 0% | 379.0 | 416,878 | Common Stock |
| Regeneron Pharmaceuticals,... | Landry E. Robert | EVP Finance CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 912.30 per share. | 02 Jan 2024 | 688 | 22,448 (0%) | 0% | 912.3 | 627,662 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 378.98 per share. | 02 Jan 2024 | 650 | 22,457 (0%) | 0% | 379.0 | 246,337 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert Landry E. | EVP Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2024 | 650 | 17,087 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharmaceuticals,... | Landry E. Robert | EVP Finance CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 888.34 per share. | 02 Jan 2024 | 421 | 22,036 (0%) | 0% | 888.3 | 373,991 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 378.98 per share. | 27 Dec 2023 | 850 | 22,419 (0%) | 0% | 379.0 | 322,133 | Common Stock |
| Regeneron Pharmaceuticals,... | E. Robert Landry | EVP Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2023 | 850 | 17,737 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 378.98 per share. | 27 Dec 2023 | 750 | 22,111 (0%) | 0% | 379.0 | 284,235 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert Landry E. | EVP Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2023 | 750 | 18,587 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharmaceuticals,... | E. Robert Landry | EVP Finance CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 884.88 per share. | 27 Dec 2023 | 612 | 21,807 (0%) | 0% | 884.9 | 541,547 | Common Stock |
| Regeneron Pharmaceuticals,... | E. Robert Landry | EVP Finance CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 872.21 per share. | 27 Dec 2023 | 542 | 21,569 (0%) | 0% | 872.2 | 472,738 | Common Stock |
| Regeneron Pharmaceuticals,... | Landry E. Robert | EVP Finance CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 856.71 per share. | 12 Dec 2023 | 6,381 | 21,084 (0%) | 0% | 856.7 | 5,466,667 | Common Stock |
| Regeneron Pharmaceuticals,... | E. Robert Landry | EVP Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 378.98 per share. | 12 Dec 2023 | 1,000 | 22,084 (0%) | 0% | 379.0 | 378,980 | Common Stock |
| Regeneron Pharmaceuticals,... | E. Landry Robert | EVP Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Dec 2023 | 1,000 | 19,337 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharmaceuticals,... | Landry Robert E. | EVP Finance CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 871.12 per share. | 12 Dec 2023 | 723 | 21,361 (0%) | 0% | 871.1 | 629,820 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert Landry E. | EVP Finance CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 844.09 per share. | 08 Dec 2023 | 2,552 | 27,465 (0%) | 0% | 844.1 | 2,154,118 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 843.79 per share. | 08 Dec 2023 | 1,013 | 30,686 (0%) | 0% | 843.8 | 854,759 | Common Stock |
| Regeneron Pharmaceuticals,... | E. Landry Robert | EVP Finance CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 844.09 per share. | 08 Dec 2023 | 669 | 30,017 (0%) | 0% | 844.1 | 564,696 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Sale of securities on an exchange or to another person at price $ 844.00 per share. | 23 Aug 2023 | 223 | 31,699 (0%) | 0% | 844 | 188,212 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 378.98 per share. | 27 Mar 2023 | 3,000 | 35,316 (0%) | 0% | 379.0 | 1,136,940 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Mar 2023 | 3,000 | 20,337 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 825.17 per share. | 27 Mar 2023 | 2,204 | 33,112 (0%) | 0% | 825.2 | 1,818,675 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 381.92 per share. | 27 Mar 2023 | 800 | 32,905 (0%) | 0% | 381.9 | 305,536 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Mar 2023 | 800 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 825.17 per share. | 27 Mar 2023 | 589 | 32,316 (0%) | 0% | 825.2 | 486,025 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Sale of securities on an exchange or to another person at price $ 825.37 per share. | 27 Mar 2023 | 243 | 31,953 (0%) | 0% | 825.4 | 200,565 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Sale of securities on an exchange or to another person at price $ 823.60 per share. | 27 Mar 2023 | 181 | 32,353 (0%) | 0% | 823.6 | 149,072 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Sale of securities on an exchange or to another person at price $ 824.54 per share. | 27 Mar 2023 | 157 | 32,196 (0%) | 0% | 824.5 | 129,453 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Sale of securities on an exchange or to another person at price $ 821.40 per share. | 27 Mar 2023 | 142 | 32,662 (0%) | 0% | 821.4 | 116,639 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Sale of securities on an exchange or to another person at price $ 822.67 per share. | 27 Mar 2023 | 128 | 32,534 (0%) | 0% | 822.7 | 105,302 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Sale of securities on an exchange or to another person at price $ 820.85 per share. | 27 Mar 2023 | 115 | 32,804 (0%) | 0% | 820.9 | 94,398 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Sale of securities on an exchange or to another person at price $ 820.46 per share. | 27 Mar 2023 | 50 | 33,023 (0%) | 0% | 820.5 | 41,023 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Sale of securities on an exchange or to another person at price $ 821.40 per share. | 27 Mar 2023 | 48 | 32,975 (0%) | 0% | 821.4 | 39,427 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Sale of securities on an exchange or to another person at price $ 819.46 per share. | 27 Mar 2023 | 39 | 33,073 (0%) | 0% | 819.5 | 31,959 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Sale of securities on an exchange or to another person at price $ 826.35 per share. | 27 Mar 2023 | 31 | 31,922 (0%) | 0% | 826.4 | 25,617 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Sale of securities on an exchange or to another person at price $ 822.56 per share. | 27 Mar 2023 | 18 | 32,957 (0%) | 0% | 822.6 | 14,806 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Sale of securities on an exchange or to another person at price $ 825.62 per share. | 27 Mar 2023 | 13 | 32,940 (0%) | 0% | 825.6 | 10,733 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Sale of securities on an exchange or to another person at price $ 818.80 per share. | 27 Mar 2023 | 10 | 32,919 (0%) | 0% | 818.8 | 8,188 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Sale of securities on an exchange or to another person at price $ 830.00 per share. | 27 Mar 2023 | 7 | 32,929 (0%) | 0% | 830 | 5,810 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Sale of securities on an exchange or to another person at price $ 829.25 per share. | 27 Mar 2023 | 4 | 32,936 (0%) | 0% | 829.3 | 3,317 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Sale of securities on an exchange or to another person at price $ 824.25 per share. | 27 Mar 2023 | 4 | 32,953 (0%) | 0% | 824.3 | 3,297 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Feb 2023 | 3,000 | 800 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 381.92 per share. | 03 Feb 2023 | 3,000 | 35,105 (0%) | 0% | 381.9 | 1,145,760 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 774.29 per share. | 03 Feb 2023 | 2,248 | 32,857 (0%) | 0% | 774.3 | 1,740,604 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Sale of securities on an exchange or to another person at price $ 764.50 per share. | 03 Feb 2023 | 739 | 32,105 (0%) | 0% | 764.5 | 564,966 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Sale of securities on an exchange or to another person at price $ 784.27 per share. | 03 Feb 2023 | 113 | 32,693 (0%) | 0% | 784.3 | 88,623 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Sale of securities on an exchange or to another person at price $ 794.61 per share. | 03 Feb 2023 | 99 | 32,210 (0%) | 0% | 794.6 | 78,666 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Sale of securities on an exchange or to another person at price $ 788.62 per share. | 03 Feb 2023 | 99 | 32,373 (0%) | 0% | 788.6 | 78,073 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Sale of securities on an exchange or to another person at price $ 786.45 per share. | 03 Feb 2023 | 85 | 32,530 (0%) | 0% | 786.4 | 66,848 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Sale of securities on an exchange or to another person at price $ 785.88 per share. | 03 Feb 2023 | 78 | 32,615 (0%) | 0% | 785.9 | 61,299 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Sale of securities on an exchange or to another person at price $ 795.41 per share. | 03 Feb 2023 | 59 | 32,151 (0%) | 0% | 795.4 | 46,929 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Sale of securities on an exchange or to another person at price $ 787.47 per share. | 03 Feb 2023 | 58 | 32,472 (0%) | 0% | 787.5 | 45,673 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Sale of securities on an exchange or to another person at price $ 783.06 per share. | 03 Feb 2023 | 51 | 32,806 (0%) | 0% | 783.1 | 39,936 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Sale of securities on an exchange or to another person at price $ 789.04 per share. | 03 Feb 2023 | 49 | 32,324 (0%) | 0% | 789.0 | 38,663 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Sale of securities on an exchange or to another person at price $ 797.43 per share. | 03 Feb 2023 | 28 | 32,105 (0%) | 0% | 797.4 | 22,328 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Sale of securities on an exchange or to another person at price $ 796.44 per share. | 03 Feb 2023 | 18 | 32,133 (0%) | 0% | 796.4 | 14,336 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Sale of securities on an exchange or to another person at price $ 790.40 per share. | 03 Feb 2023 | 10 | 32,314 (0%) | 0% | 790.4 | 7,904 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Sale of securities on an exchange or to another person at price $ 791.00 per share. | 03 Feb 2023 | 3 | 32,311 (0%) | 0% | 791 | 2,373 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Sale of securities on an exchange or to another person at price $ 793.50 per share. | 03 Feb 2023 | 2 | 32,309 (0%) | 0% | 793.5 | 1,587 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2022 | 14,222 | 14,222 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2022 | 3,853 | 32,844 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 381.92 per share. | 08 Dec 2022 | 3,000 | 31,744 (0%) | 0% | 381.9 | 1,145,760 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Dec 2022 | 3,000 | 3,800 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 768.54 per share. | 08 Dec 2022 | 2,261 | 29,483 (0%) | 0% | 768.5 | 1,737,669 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 753.28 per share. | 08 Dec 2022 | 492 | 28,991 (0%) | 0% | 753.3 | 370,614 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 381.92 per share. | 01 Dec 2022 | 2,500 | 31,244 (0%) | 0% | 381.9 | 954,800 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2022 | 2,500 | 6,800 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 760.35 per share. | 01 Dec 2022 | 1,890 | 29,354 (0%) | 0% | 760.4 | 1,437,062 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Sale of securities on an exchange or to another person at price $ 756.50 per share. | 01 Dec 2022 | 582 | 28,772 (0%) | 0% | 756.5 | 440,283 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Sale of securities on an exchange or to another person at price $ 759.88 per share. | 01 Dec 2022 | 16 | 28,756 (0%) | 0% | 759.9 | 12,158 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Sale of securities on an exchange or to another person at price $ 760.17 per share. | 01 Dec 2022 | 12 | 28,744 (0%) | 0% | 760.2 | 9,122 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2022 | 2,000 | 9,300 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 381.92 per share. | 31 Oct 2022 | 2,000 | 30,744 (0%) | 0% | 381.9 | 763,840 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 751.24 per share. | 31 Oct 2022 | 1,518 | 29,226 (0%) | 0% | 751.2 | 1,140,382 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Sale of securities on an exchange or to another person at price $ 761.36 per share. | 31 Oct 2022 | 119 | 28,780 (0%) | 0% | 761.4 | 90,602 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Sale of securities on an exchange or to another person at price $ 755.46 per share. | 31 Oct 2022 | 81 | 29,024 (0%) | 0% | 755.5 | 61,192 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Sale of securities on an exchange or to another person at price $ 754.39 per share. | 31 Oct 2022 | 80 | 29,105 (0%) | 0% | 754.4 | 60,351 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Sale of securities on an exchange or to another person at price $ 759.39 per share. | 31 Oct 2022 | 70 | 28,912 (0%) | 0% | 759.4 | 53,157 | Common Stock |
| Regeneron Pharmaceuticals,... | Robert E. Landry | EVP Finance CFO | Sale of securities on an exchange or to another person at price $ 758.19 per share. | 31 Oct 2022 | 42 | 28,982 (0%) | 0% | 758.2 | 31,844 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges